FarmaMondo and Accendatech USA Inc. partnered to initiate a Managed Access Program for the compassionate supply of ACT-001 for patients in Hong Kong.
Under the terms of the Agreement, FarmaMondo will exclusively manage key elements of the program including regulatory oversight, logistics and access management, on a fee for service model. It brings great hope for patients who may gain therapeutic options when other alternatives do not currently exist for them.
On the strategic level, once again the agreement represents the strong trust of the industry in the services offered by the FarmaMondo Group. After several years of engagements mostly on the paid access segment we are happy to accommodate such partnerships on the earlier part of the product lifecycle while contributing our developing expertise for more patients in need.
FarmaMondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.
For more information about FarmaMondo please visit: www.farmamondo.com
Accendatech Co. Ltd., the parental company of Accendatech USA Inc. founded in 2008, is a fast-growing biotech company focusing on discovery and development of oncological and non-oncological drugs. It is a publicly traded company in Tianjin OTC (China). Accendatech USA Inc. was founded in Houston Texas in 2017 for developing anticancer drugs in USA.
For more information about Accendatech please visit: http://www.accendatechusa.com/